Botulax and the US development

Document Type

Article

Publication Date

10-27-2022

Publication Title

Dermatological Reviews

Abstract

Background: LetibotulinumtoxinA (LeBA; Hugel Inc.) is a novel botulinum toxin derived from the Clostridium botulinum strain CBFC26. It is marketed as Botulax with cosmetic and neuromuscular indications.Materials and Methods: This review article summarizes the current literature regarding the key efficacy and safety studies regarding LeBA. It also highlights unique features of LeBA regarding its physical properties, onset with use, duration of effect, and immunogenicity.Results: LeBA's cosmetic use shows efficacy in decreasing glabellar lines and crow's feet. It has also shown efficacy in treating post-stroke upper limb spasticity, blepharospasm, and dynamic equinus foot deformities in children with cerebral palsy.Discussion: LeBA is a novel BoNT type A that is currently indicated for treatment of both neuromuscular disease and for cosemetic purposes. LeBA has displayed equivocal efficacy and a similar safety profile when compared to other botulinum neurotoxin preparations.

First Page

231

Last Page

235

Volume

3

Issue

4

Rights

© 1999-2026 John Wiley & Sons, Inc or related companies

Link to Full Text

Share

COinS